BGI Genomics Re-Files to Raise $250 Million in Shenzhen IPO

BGI Genomics, the Shenzhen genomics sequencing company, has filed to IPO on the Shenzhen Chi-Next exchange with a proposed target of raising $250 million. Late last year, the Shenzhen Exchange rejected a similar application from BGI Genomics because its documentation was not complete. The previous transaction was rumored to be much larger -- about $600 million. BGI Genomics, a division of BGI Holdings, includes several of BGI's revenue producing divisions, such as BGI Tech, its contract genomics sequencing service subsidiary, and BGI Dx, its clinical diagnostic division. More details.... Share this with colleagues: // //